TITLE

Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome

AUTHOR(S)
Kamei, Koichi; Okada, Mari; Sato, Mai; Fujimaru, Takuya; Ogura, Masao; Nakayama, Makiko; Kaito, Hiroshi; Iijima, Kazumoto; Ito, Shuichi
PUB. DATE
July 2014
SOURCE
Pediatric Nephrology;Jul2014, Vol. 29 Issue 7, p1181
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Calcineurin inhibitors (CIs) with/without intravenous methylprednisolone pulse therapy (MPT) constitute the standard treatment for childhood-onset, steroid-resistant nephrotic syndrome (SRNS). However, some patients fail to achieve remission. We treated SRNS patients resistant to CIs and MPT with additional rituximab combined with MPT and immunosuppressive agents. Methods: Ten patients (aged 2-14 years) with CI- and MPT-resistant SRNS were enrolled. Patients were administered rituximab (1-4 doses; 375 mg/m) followed by MPT (30 mg/kg/day of methylprednisolone for 3 consecutive days) once every 2-4 weeks until complete remission (CR). We analyzed clinical outcome and safety. Results: Six patients received a single dose of rituximab, 2 received two doses, and 2 received four doses. Seven patients achieved CR, 1 achieved partial remission, and 2 showed no response. Although 2 patients with no response progressed to end-stage renal failure, 7 patients with CR preserved normal renal function without proteinuria at the last observation. There were two serious adverse events. Conclusions: Additional rituximab combined with conventional MPT and immunosuppressive agents is a promising option for overcoming refractory SRNS. Aggressive B cell suppression by rituximab may ameliorate resistance to conventional treatments and a cocktail of other immunosuppressive agents, such as CIs, MMF, mizoribine, may be beneficial. However, as intense immunosuppression may cause serious adverse events, further evaluation is necessary.
ACCESSION #
96127211

 

Related Articles

  • Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Straatmann, Caroline; Ayoob, Rose; Gbadegesin, Rasheed; Gibson, Keisha; Rheault, Michelle; Srivastava, Tarak; Tran, Cheryl; Gipson, Debbie; Greenbaum, Larry; Smoyer, William; Vehaskari, V. // Pediatric Nephrology;Aug2013, Vol. 28 Issue 8, p1235 

    Background: Idiopathic nephrotic syndrome (NS) in children is classified as steroid sensitive or steroid resistant. Steroid sensitivity typically portends a low risk of permanent renal failure. However, some initially steroid-sensitive patients later develop steroid resistance. These patients...

  • Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Kamei, Koichi; Ogura, Masao; Sato, Mai; Sako, Mayumi; Iijima, Kazumoto; Ito, Shuichi // Pediatric Nephrology;Jan2016, Vol. 31 Issue 1, p89 

    Background: Rituximab (RTX) is known to be effective for the treatment of refractory steroid-dependent nephrotic syndrome (SDNS). However, there are insufficient data on the risk factors for relapse and long-term outcome after RTX treatment. Methods: We administered a single dose of RTX to...

  • Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. Tieu, Jennifer D.; Schmidt, Sarah A.; Miller, Jamie L.; Kupiec, Katherine E.; Skrepnek, Grant H.; Liu, Connie; Smith, Winter J. // Journal of Oncology Pharmacy Practice;Apr2019, Vol. 25 Issue 3, p520 

    Background Clostridium difficile infection treatment guidelines exist for immunocompetent patients; however, there is a paucity of data evaluating clinical outcomes and time to C. difficile-associated diarrhea resolution in neutropenic patients. Objective To assess clinical outcomes in...

  • Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients. Uncu, Doğan; Aksoy, Sercan; Çetin, Bülent; Yetişyiğit, Tarkan; Özdemir, Nuriye; Berk, Veli; Dane, Faysal; İnal, Ali; Harputluoğlu, Hakan; Budakoğlu, Burçin; Koca, Doğan; Sevinç, Alper; Cihan, Şener; Gök Durnalı, Ayşe; Özkan, Metin; Öztürk, Mehmet Akif; Işıkdoğan, Abdurrahman; Büyükberber, Süleyman; Benekli, Mustafa; Köş, Tuğba // Oncology;Mar2013, Vol. 84 Issue 4, p240 

    Objective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. Methods: Patients who received oxaliplatin-containing regimens after curative resection for colorectal...

  • Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Tellier, Stéphanie; Brochard, Karine; Garnier, Arnaud; Bandin, Flavio; Llanas, Brigitte; Guigonis, Vincent; Cailliez, Mathilde; Pietrement, Christine; Dunand, Olivier; Nathanson, Sylvie; Bertholet-Thomas, Aurélia; Ichay, Lydia; Decramer, Stéphane // Pediatric Nephrology;Jun2013, Vol. 28 Issue 6, p911 

    Background: Rituximab (RTX) has recently showed promising results in the treatment of steroid-dependent idiopathic nephrotic syndrome (SDNS). Methods: This was a retrospective multicenter study of 18 children treated with RTX for SDNS, with a mean follow-up of 3.2 years. RTX was introduced...

  • Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Hamasaki, Yuko; Yoshikawa, Norishige; Nakazato, Hitoshi; Sasaki, Satoshi; Iijima, Kazumoto; Nakanishi, Koichi; Matsuyama, Takeshi; Ishikura, Kenji; Ito, Shuichi; Kaneko, Tetsuji; Honda, Masataka // Pediatric Nephrology;May2013, Vol. 28 Issue 5, p765 

    Background: Cyclosporine has improved remission rates in children with steroid-resistant nephrotic syndrome (SRNS). However, little prospective long-term follow-up data is available. Methods: We prospectively followed and analyzed 5-year outcomes of all 35 patients enrolled in our previous...

  • Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients. Li, Yi; Xi, Han-xu; Zhu, Sha; Yu, Na; Wang, Jing; Li, Yan; Yu, Guo-pei; Ma, Xie-min; Zhang, Jun; Zhao, Lue-ping // Chinese Journal of Integrative Medicine;Aug2014, Vol. 20 Issue 8, p570 

    Objective: To evaluate the cost-effectiveness of combining Chinese medicine (CM) with Western medicine (WM) for ischemic stroke patients. Methods: Hospitalization summary reports between 2006 and 2010 from eight hospitals in Beijing were used to analyze the length of stay (LOS), cost per stay...

  • Should we consider MMF therapy after rituximab for nephrotic syndrome? Filler, Guido; Huang, Shih-Han; Sharma, Ajay // Pediatric Nephrology;Oct2011, Vol. 26 Issue 10, p1759 

    The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum...

  • Zidovudine as Modern Day Salvage Therapy for HIV Infection. Kupiec, Katherine E.; Johnson, James W.; Barroso, Luis F.; Wrenn, Rebekah H.; Williamson, John C. // AIDS Patient Care & STDs;Nov2014, Vol. 28 Issue 11, p570 

    Resistance to the first-line NRTIs, tenofovir and emtricitabine, does not generally confer resistance to zidovudine. The objective of this study was to describe the efficacy of zidovudine as modern day salvage antiretroviral therapy. This was a single-center, retrospective, observational, cohort...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics